Sudarshan Pharma Industries Moves to NSE Main Board

Total Securities: 254,470,600
Effective Date: October 27, 2026

Reader Takeaway: Migration to the main board enhances visibility and institutional participation but comes with stricter regulatory disclosure requirements.

What just happened

Sudarshan Pharma Industries Ltd has successfully secured approval from the National Stock Exchange (NSE) to migrate its equity shares from the BSE SME platform to the NSE Main Board. The company received the formal notification from the exchange on October 23, 2026, confirming that trading on the new platform will commence on October 27, 2026. The company will trade under the symbol 'SUDARSHAN' with a face value of Re 1 per share.

Why this matters

Migrating to a main board is a significant step for companies graduating from the SME segment. It typically signals to the market that the business has reached a higher level of maturity. For investors, this move is generally positive as it increases the company's visibility, broadens the pool of potential institutional investors, and often leads to improved trading liquidity compared to the SME segment.

Lock-in details

The exchange has outlined specific lock-in periods for the equity shares involved in the migration:

• 128,226,490 shares are locked in until December 31, 2027.
• 9,000,000 shares are locked in until February 20, 2028.
• 117,244,110 shares are free from lock-in restrictions.

What changes now

As a company listed on the Main Board, Sudarshan Pharma will be required to adhere to more stringent disclosure norms. Specifically, the company must ensure its financial result submissions are strictly in compliance with Regulation 33 of the SEBI (LODR) Regulations, 2015. This level of oversight provides investors with greater transparency regarding the company’s financial health and governance standards.